RSVpreF3
Phase 3
SanofiRSVpreF3 is one of 14 therapeutic programs targeting Respiratory Syncytial Virus Infection. It is currently in Phase 3.
1
Indications
0
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
15 competitors in Respiratory Syncytial Virus Infection
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Virazole
CConrado Roberto Hoffmann Filho
Approved
Fluzone
SanofiPhase 3
SYNAGIS
SSwedish Orphan Biovitrum
Phase 3
Lagevrio
Merck & Co.Phase 2
Aluminum Phosphate
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Ad26.rsv.pref
Johnson & JohnsonPhase 2
RSVpreF3
SanofiPhase 3
JNJ-53718678
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for RSVpreF3. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3
- Company